Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Int J Oncol
    October 2022
  1. WANG Y, Han A, Chen E, Singh RK, et al
    [Corrigendum] The cranberry flavonoids PAC DP9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.
    Int J Oncol. 2022;61.
    >> Share

  2. LI R, Wang Y, Xu Y, He X, et al
    [Retracted] Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
    Int J Oncol. 2022;61.
    >> Share

  3. BJERSAND K, Blom K, Poromaa IS, Stalberg K, et al
    Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome.
    Int J Oncol. 2022;61.
    >> Share

  4. KIM SH, Baek KH
    Ovarian tumor deubiquitinase 6A regulates cell proliferation via deubiquitination of nucleolin and caspase7.
    Int J Oncol. 2022;61.
    >> Share

    July 2022
  5. FEDIER A, Maggi N, Tozzi A, Disler M, et al
    Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Int J Oncol. 2022;61.
    >> Share

    May 2022
  6. ZHANG R, Roque DM, Reader J, Lin J, et al
    Combined inhibition of IL6 and IL8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
    Int J Oncol. 2022;60.
    >> Share

  7. LAVORO A, Scalisi A, Candido S, Zanghi GN, et al
    Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    Int J Oncol. 2022;60.
    >> Share

    March 2022
  8. SINGH T, Neal A, Dibernardo G, Raheseparian N, et al
    Efficacy of birinapant in combination with carboplatin in targeting platinumresistant epithelial ovarian cancers.
    Int J Oncol. 2022;60.
    >> Share

    July 2021
  9. CHAUVIN M, Garambois V, Choblet S, Colombo PE, et al
    Anti-Mullerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
    Int J Oncol. 2021;59.
    >> Share

  10. FALZONE L, Scandurra G, Lombardo V, Gattuso G, et al
    A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
    Int J Oncol. 2021;59.
    >> Share

    May 2021
  11. THONGCHOT S, Jamjuntra P, Therasakvichya S, Warnnissorn M, et al
    Interleukin8 released by cancerassociated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells.
    Int J Oncol. 2021;58.
    >> Share

    September 2020
  12. LIU J, Liu D, Liu JJ, Zhao C, et al
    [Corrigendum] Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2020 Sep 28. doi: 10.3892/ijo.2020.5129.
    >> Share

  13. LIU L, Yuan L, Huang D, Han Q, et al
    miR126 regulates the progression of epithelial ovarian cancer in vitro and in vivo by targeting VEGFA.
    Int J Oncol. 2020;57:825-834.
    >> Share

    April 2020
  14. GUO F, Zhang K, Li M, Cui L, et al
    miR5083p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.
    Int J Oncol. 2020 Apr 27. doi: 10.3892/ijo.2020.5055.
    >> Share

    January 2020
  15. BU H, Li Y, Jin C, Yu H, et al
    Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4959.
    >> Share

  16. FENG Y, Tang Y, Mao Y, Liu Y, et al
    PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4958.
    >> Share

    December 2019
  17. LEE SY, Kwon J, Woo JH, Kim KH, et al
    Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.
    Int J Oncol. 2019 Dec 23. doi: 10.3892/ijo.2019.4949.
    >> Share

    November 2019
  18. LIU Q, Liu H, Li L, Dong X, et al
    ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
    Int J Oncol. 2019 Nov 14. doi: 10.3892/ijo.2019.4913.
    >> Share

  19. BAI Y, Li LD, Li J, Chen RF, et al
    A FXYD5/TGFbeta/SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
    Int J Oncol. 2019 Nov 13. doi: 10.3892/ijo.2019.4911.
    >> Share

    September 2019
  20. YE W, Ni Z, Yicheng S, Pan H, et al
    Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNAMeg3/miR421/PDGFRA axis.
    Int J Oncol. 2019 Sep 30. doi: 10.3892/ijo.2019.4887.
    >> Share

  21. LI R, Wang Y, Xu Y, He X, et al
    Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
    Int J Oncol. 2019 Sep 10. doi: 10.3892/ijo.2019.4875.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016